Pernix Therapeutics Stock: good entry point

Pernix Therapeutics Stock (PTX) closed at $0.59 for the week, down more than 9% from its close on 26 Aug 2016. PTX has been trending lower since 19 Aug 2016. What has caused PTX stock price to head south?

Well, in my most humble opinions, it has all to do with the fact that the so-called "Buyout news" of Pernix Therapeutics turn out nothing to be just unfounded rumours. In the end, it seems that there is no fact to the news that Concordia or any other potential suitors have won the bid for Pernix Therapeutics. I believe investors are disappointed and looking at the debt amount of Pernix Therapeutics, I think they decide to come out from the stock for a while just to be safe while they assess for themselves the prospects of PTX.

In my opinion, despite the sell-down, I believe there is nothing wrong with Pernix Therapeutics company, what is wrong is the current price of PTX stock as it does not justify the potential of the stock. Let me outline my opinions below:

1) One, the rumours of a possible buy-out has been there on the horizon, some say it is not a matter of whether there is a Buyout but rather a matter of when, it might all just have to do with finding buyers.

2) There can be no talk about a "Buy out" if there are no attractive attributes of a company. Look at Pernix's products and its plans for the pipeline.

3) What is most encouraging for me is that John Sedor who previously occupied a board member seat in Pernix Therapeutics become the CEO. His record in restructuring a company for a buy-out is well-documented and as a result many see having Sedor on board Pernix Therapeutics just pave or facilitate the way forward for a buyout of Pernix Therapeutics.

4) And John Sedor has already started restructuring his company, cutting off the redundancy and beefing up his sale team. Along the process, there can be the unpleasant, undeniable lay-outs but ultimately, Pernix Therapeutics would become a better company.

5) Last but least, a company's profits is as good as its products. Pernix Therapeutic boosts a good slew of products

To summarize, I believe the price of PTX now does not justify the potential of Pernix Therapeutics. It is a good opportunity to Buy in, be it in tranches or for the investors most confident of the company, to do so in a convincing manner.
If you wish to receive FREE Regular Newsletters about K8 Investing's views on US stocks and investments, please click this link here. Also, if like my post, please Like K8Investing Facebook or K8Investing Twitter page to get instant updates about the search for the next US multi-bagger stocks!

PERNIX THERAPEUTICS STOCK (PTX): AN UPDATE

Dear reader, it has been some time since I am here on K8 Investing. But my focus has really been on spotting multi-baggers and pretty much, my focus is on PERNIX THERAPEUTICS STOCK (PTX), a stock which in my opinion could be a multi-bagger. My reasons behind PTX being a multi-bagger have been well-documented, just click on the "PTX" label at the bottom of the post.

Undervalued, Dividends-paying, discounted US stocks

These are the stocks which have:

a) a minimum dividend yield of 4%

b) is more than 80% below the stock’s 52-week high

c) and has a positive Price-to-book ratio below 1 (that is undervalued)

Pernix Therapeutics Holdings: a multi-bagger in the making

Pernix Therapeutics Holdings (PTX) stock shed 10% on 15 July 2016 as investors focused on a piece of news bout Pernix Therapeutics Holdings discussing debt restructuring with its creditors. If you have not heard about the news, you can refer to this link here.

VALEANT PHARMACEUTICAL STOCK: WHY I WAS CORRECT?

In my previous post on Valeant Pharmaceutical stock (VRX), I told readers that the immediate resistance of VRX was $24.30 and on 7 Jul 2016, VRX went to a high of $24.25 but not able to cross above this resistance. Valeant Pharmaceutical stock closed at $22.86 on 15 Jul 2016.

VALEANT PHARMACEUTICALS STOCK

At of this time in writing, VALEANT PHARMACEUTICALS stock inched up around 4% and traded at around $22.51. I read a very optimistic post in CNA Finance about Valeant Pharmaceuticals stock and as much I like this stock, I could not help but think that the trading in Valeant Pharmaceuticals is not easily grasped just by looking at the stock price movement. I would think a good price to get this stock in more quantity will be below $20. What do you think? If you like my post, please Like K8Investing Facebook or K8Investing Twitter page to get instant updates about the search for the next US multi-bagger stocks!If you wish to receive FREE Regular Newsletters about K8 Investing's views on US stocks and investments, please click this link here.

LINE (LN) STOCK IPO

Today, the Japanese messaging app, LINE (LN) debuted on NYSE in one of the most expensive IPOs for year 2016. As expected, to much fanfare, LINE stock rallied a good 30% over its around $32 IPO price as of this time in writing ($42.95). There is lots of excitment, expectation about this tech stock as many wonder whether LINE will follow the foot-steps of previous tech start-ups like Facebook, Amazon and become multi-baggers.